Coblopasvir hydrochloride

Synonyma:: Coblopasvir dihydrochloride;Coblopasvir dihydrochloride(1312608-46-0 Free base);HCV Protease,inhibit,Coblopasvir dihydrochloride,KW136,Coblopasvir,HCV,chronic hepatitis C virus infection,pangenotypic regimen,Hepatitis C virus,KW-136,NS5A,KW 136,Inhibitor;Carbamic acid, N-[(1S)-1-[[(2S)-2-[5-[4-[7-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-imidazol-5-yl]-1,3-benzodioxol-4-yl]phenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-, methyl ester, hydrochloride (1:2)

Request For Quotation

Eigenschaften Sicherheit Verwendungswort Produktionsfirma 8

Coblopasvir hydrochloride Eigenschaften

L?slichkeit: DMSO : 50 mg/mL (58.42 mM; ultrasonic and warming and heat to 60°C)

Global( 8)Lieferanten

Firmenname	Telefon	E-Mail	Land	Produktkatalog	Edge Rate
TargetMol Chemicals Inc.	+1-781-999-5354 +1-00000000000	marketing@targetmol.com	United States	32161	58
Aladdin Scientific	+1-+1(833)-552-7181	sales@aladdinsci.com	United States	52924	58
Wuxi Donghe Pharmaceutical Technology Co., Ltd.	63313187 15358055255	63313187@qq.com	China	1987	58
TargetMol Chemicals Inc.	4008200310	marketing@tsbiochem.com	China	24644	58
Shanghai Maclean Biochemical Technology Co., LTD	021-50706066 15221275939	shenlinxing@macklin.cn	China	29944	58
Shanghai Yifei Biotechnology Co. , Ltd.	021-65675885 18964387627	customer_service@efebio.com	China	11974	58
RD International Technology Co., Limited	18024082417	market@ubiochem.com	China	9266	58
Nanjing Shizhou Biology Technology Co.,Ltd	025-85560043 15850508050	cindy.huang@synzest.com	China	12000	58

Carbamic acid, N-[(1S)-1-[[(2S)-2-[5-[4-[7-[2-[(2S)-1-[(2S)-2-[(methoxycarbonyl)amino]-3-methyl-1-oxobutyl]-2-pyrrolidinyl]-1H-imidazol-5-yl]-1,3-benzodioxol-4-yl]phenyl]-1H-imidazol-2-yl]-1-pyrrolidinyl]carbonyl]-2-methylpropyl]-, methyl ester, hydrochloride (1:2)
Coblopasvir dihydrochloride
Coblopasvir dihydrochloride(1312608-46-0 Free base)
HCV Protease,inhibit,Coblopasvir dihydrochloride,KW136,Coblopasvir,HCV,chronic hepatitis C virus infection,pangenotypic regimen,Hepatitis C virus,KW-136,NS5A,KW 136,Inhibitor
1966138-53-3
C41H51ClN8O8